Globus Medical (GMED) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Globus Medical reported revenue of $769.05 million for the quarter ended September 2025, reflecting a year-over-year increase of 22.9% [1] - The company's EPS was $1.18, up from $0.83 in the same quarter last year, indicating a significant improvement [1] - The reported revenue exceeded the Zacks Consensus Estimate of $733.45 million by 4.85%, while the EPS surpassed the consensus estimate of $0.79 by 49.37% [1] Revenue Breakdown - International revenue reached $151.42 million, exceeding the average estimate of $144.37 million by analysts, marking a 16.6% increase year-over-year [4] - U.S. revenue was reported at $617.63 million, surpassing the average estimate of $589.84 million, with a year-over-year growth of 24.6% [4] - Net sales in the Enabling Technologies category were $28.04 million, below the average estimate of $40.23 million, representing a decline of 26.8% year-over-year [4] - Musculoskeletal Solutions generated $741.01 million in net sales, exceeding the average estimate of $693.98 million, with a year-over-year increase of 26.2% [4] Stock Performance - Shares of Globus Medical have returned +1.8% over the past month, compared to a +1.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]